Amgen reported flat to slightly declining revenues but achieved a 9% increase in EPS and raised its non-GAAP earnings guidance, signaling strong cost management and successful new product performance. Management's optimistic tone and strategic focus on innovation suggest positive investor sentiment in the short term despite some revenue challenges.

[1]